21 March 2024
21 March 2024
Lilly says that the FDA wants to look closer at efficacy implications of the Phase III donanemab trial design before giving the green light.
The study aims to determine the efficacy, safety, and tolerability of psilocybin in treating MDD.
The trial assessed the rate of geographic atrophy expansion during the minocycline treatment phase against the baseline rate.
In December 2023, the Taiwan FDA granted IND clearance to commence the Phase II trial.
Various data indicates that the healthcare industry is reaching a critical point.
The development follows a positive recommendation from the trial’s independent drug safety monitoring board.
A recent retrospective cohort study's findings saw a high incidence of osteoporosis in patients with vitiligo compared with their counterparts without.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
